| Literature DB >> 24660134 |
Joel Heisler1, Lindsay Elvir1, Farah Barnouti1, Erica Charles1, Tom D Wolkow2, Radha Pyati1.
Abstract
ABSTRACT: Gaining a full understanding of the mechanisms of action of natural products as therapeutic agents includes observing the effects of natural products on cellular morphology, because abnormal cellular morphology is an important aspect of cellular transformations that occur as part of disease states. In this study a set of natural products was examined in search of small molecules that influence the cylindrical morphology of fission yeast Schizosaccharomyces pombe. Imaging flow cytometry of large populations of S. pombe exposed to natural products captured cell images and revealed changes in mean length and aspect ratio of cells. Several natural products were found to alter S. pombe's morphology relative to control, in terms of elongating cells, shrinking them, or making them more round. These results may facilitate future investigations into methods by which cells establish and maintain specific shapes. GRAPHICAL ABSTRACT: Gaining a full understanding of the mechanisms of action of natural products as therapeutic agents includes observing the effects of natural products on cellular morphology, because abnormal cellular morphology is an important aspect of cellular transformations that occur as part of disease states. In this study a set of natural products was examined in search of small molecules that influence the cylindrical morphology of fission yeast Schizosaccharomyces pombe. Imaging flow cytometry of large populations of S. pombe exposed to natural products captured cell images and revealed changes in mean length and aspect ratio of cells. Several natural products were found to alter S. pombe's morphology relative to control, in terms of elongating cells, shrinking them, or making them more round. These results may facilitate future investigations into methods by which cells establish and maintain specific shapes.Entities:
Keywords: Aspect ratio; Fission yeast; Imaging flow cytometry; Morphology; Natural products; Schizosaccharomyces pombe
Year: 2014 PMID: 24660134 PMCID: PMC3956978 DOI: 10.1007/s13659-014-0004-8
Source DB: PubMed Journal: Nat Prod Bioprospect ISSN: 2192-2209
Fig. 1Natural products from NCI Open Chemical Repository Collection Natural Products Set II
Fig. 2Images collected with FlowCAM IFC. Panels contain most elongated images from each representative sample, for comparison. AS. pombe cells subjected to khellin (NSC#8519) exhibiting with lengths ranging from 10.29 to 11.51 µm represented. BS. pombe cells subjected to no NP (control) with lengths from 9.09 to 9.88 µm
Cell length and aspect ratio relative to control for natural products
| Natural product and trial number | L/Lca (%) | AR/ARcb (%) | Mean L/Lc (%) | Mean AR/ARc (%) |
|---|---|---|---|---|
| Khellin | ||||
| Trial 1 | 121.7 | 94.1 | 114.7 ± 9.2 | 97.5 ± 8.0 |
| Trial 2 | 112.6 | 101.6 | ||
| Trial 3 | 109.7 | 96.6 | ||
| Artemisinine | ||||
| Trial 1 | 101.0 | 106.8 | 103.9 ± 3.6 | 106.0 ± 2.1 |
| Trial 2 | 106.0 | 106.5 | ||
| Trial 3 | 104.8 | 104.7 | ||
| Beta-lapachone | ||||
| Trial 1 | 103.7 | 98.6 | 102.9 ± 5.3 | 98.9 ± 3.9 |
| Trial 2 | 100.4 | 99.3 | ||
| Trial 3 | 104.7 | 98.9 | ||
| Lonchocarpic acid | ||||
| Trial 1 | 102.7 | 109.5 | 101.4 ± 2.8 | 111.5 ± 2.7 |
| Trial 2 | 101.5 | 112.0 | ||
| Trial 3 | 99.9 | 113.0 | ||
| Castanospermine | ||||
| Trial 1 | 99.9 | 100.3 | 101.0 ± 4.8 | 98.9 ± 4.5 |
| Trial 2 | 100.9 | 100.3 | ||
| Trial 3 | 102.0 | 96.3 | ||
| Curcumin | ||||
| Trial 1 | 101.4 | 103.9 | 100.5 ± 5.0 | 101.6 ± 4.5 |
| Trial 2 | 101.9 | 99.8 | ||
| Trial 3 | 98.2 | 101.0 | ||
| Glaucarubine | ||||
| Trial 1 | 92.6 | 102.5 | 98.1 ± 6.6 | 100.9 ± 4.3 |
| Trial 2 | 101.2 | 101.2 | ||
| Trial 3 | 100.5 | 99.2 | ||
| Triptolide | ||||
| Trial 1 | 97.3 | 101.5 | 98.0 ± 5.8 | 99.3 ± 7.5 |
| Trial 2 | 98.5 | 96.9 | ||
| Trial 3 | 98.1 | 99.6 | ||
| Parthenolide | ||||
| Trial 1 | 103.4 | 89.6 | 98.0 ± 4.9 | 91.4 ± 2.8 |
| Trial 2 | 94.6 | 91.8 | ||
| Trial 3 | 95.9 | 92.7 | ||
| Michellamine B | ||||
| Trial 1 | 94.5 | 90.3 | 97.0 ± 2.5 | 92.9 ± 3.4 |
| Trial 2 | 98.0 | 95.1 | ||
| Trial 3 | 98.5 | 93.3 | ||
| Tetrocarcin A | ||||
| Trial 1 | 96.2 | 99.7 | 96.7 ± 1.6 | 99.4 ± 2.7 |
| Trial 2 | 95.9 | 100.2 | ||
| Trial 3 | 98.0 | 98.2 | ||
| Bactobolin | ||||
| Trial 1 | 95.7 | 99.3 | 92.2 ± 6.3 | 97.6 ± 2.9 |
| Trial 2 | 95.8 | 97.2 | ||
| Trial 3 | 85.0 | 96.4 | ||
| Phleomycin [ | 157.9 ± 17.5 | 64.6 ± 13.1 | ||
aL/Lc = mean length of NP-exposed cells divided by mean length of control cells (not exposed to NP), as a percentage. Both NP-exposed and control measurements were performed in triplicate
bAR/ARc = mean aspect ratio of NP-exposed cells divided by mean length of control cells (not exposed to NP), as a percentage